Small Molecule, peptides, antibody therapies, contract analytical

Oncotherapy Science, Inc. is focused on advancing cancer treatment through innovative technologies that leverage genome-based drug discovery and precision medicine. The company employs laser microbeam microdissection (LMM) to isolate pure populations of cancer cells from tissue samples, enabling accurate gene expression analysis. This is complemented by a proprietary cDNA microarray system that provides high sensitivity and specificity in profiling nearly all human genes. By identifying cancer-specific genes that are over-expressed in malignant cells but not in normal tissues, Oncotherapy aims to develop targeted therapies with minimal adverse effects. Their research emphasizes the importance of understanding gene functions through RNA interference, which aids in selecting viable targets for drug development.

In their drug development pipeline, Oncotherapy is advancing several promising candidates, including OTS167, a small-molecule drug targeting the maternal embryonic leucine zipper kinase (MELK), which is crucial for cancer stem cell maintenance. Clinical studies are underway for various cancers, including breast cancer and leukemia, demonstrating OTS167's potential efficacy and safety. Additionally, the company is exploring cancer peptide vaccines, such as S-588410, which has shown improved overall survival in specific patient subgroups. Oncotherapy is also developing therapeutic antibodies, with ongoing studies for conditions like synovial sarcoma. Through these multifaceted approaches, Oncotherapy Science is committed to enhancing cancer treatment outcomes and contributing to the broader field of precision medicine.

Japan

OncoTherapy Science, Inc. provides pharmaceutical companies with yielded drug candidates by using outcomes obtained from joint research with universities and companies. These outcomes include oncogene information isolated by comprehensive analysis of genes specifically expressed in cancer cells and functional analysis information of proteins produced by oncogenes and other gene products. We have also been performing research and development business regarding medications.

Cancer

Digestive System Diseases

Nervous System Diseases

Urogenital Diseases

Oncotherapy Science

Esophageal cancer

S-588410

Biologics

Vaccines

Bladder cancer

Head and neck cancer

S-488210

Solid tumor/s

S-588210

Gastric cancer

OTSGC-A24

Synovial sarcoma

OTSA101

Antibodies

Alzheimer's disease

OncoTherapy Science Drug #1 (Anti-a beta Peptide Antibody)

Breast cancer

Leukemia

OTS167

Small Molecule Pharmaceuticals

Peptide Therapies

RNAi

Stem Cells

Therapeutic

Vendor

Oncotherapy Science

Company Details